ISR’s leading technology comprises a novel treatment for HIV/AIDS infected patients. A positive Phase I/IIa clinical trial has been completed and ISR has patented the use of ISR-48
ISR is currently developing a second line of chemical entities were ISR-50 is the lead candidate.
Our mission is to find cures for viral infections and their complications through the development of drugs targeting the immune system.
At ISR we believe we have the breadth and depth of expertise required to ensure our vision becomes a reality.
Worldwide, 2 million new cases of HIV occurred in 2014. About 37 million people live with HIV but only 15 million have access to treatment.